利伐沙班与其他抗凝药相比的重度异常子宫出血风险
该回顾性队列研究基于FDA Sentinel系统(2010年10月至2015年9月),纳入18岁以上新启用利伐沙班、阿哌沙班、达比加群或华法林的静脉血栓栓塞或房颤/房扑女性,比较因阴道出血导致输血或手术干预的重度异常子宫出血风险。结果显示利伐沙班较达比加群、阿哌沙班和华法林增加手术干预风险,且无妇科病史者中该风险仍存在。
要点
- 利伐沙班较达比加群、阿哌沙班和华法林增加手术干预风险。
- 利伐沙班仅较达比加群增加输血风险(HR 1.49)。
- 无妇科病史女性中利伐沙班手术干预风险仍高于其他抗凝药。
核心结论
- 利伐沙班使用与其他DOAC或华法林相比增加重度异常子宫出血风险。
- 无潜在妇科疾病的女性中利伐沙班风险仍增加。
研究设计与样本
- FDA Sentinel系统回顾性队列研究,时间范围2010年10月至2015年9月。
- 纳入18岁以上新启用DOAC或华法林的VTE或AF女性。
- 采用倾向评分分层Cox比例风险回归估计HR,进行四组两两比较。
主要发现
- 手术干预风险:利伐沙班 vs 达比加群 HR 1.19(95%CI 1.03-1.38)。
- 手术干预风险:利伐沙班 vs 阿哌沙班 HR 1.23(95%CI 1.04-1.47)。
- 手术干预风险:利伐沙班 vs 华法林 HR 1.34(95%CI 1.22-1.47)。
- 输血风险:利伐沙班 vs 达比加群 HR 1.49(95%CI 1.03-2.17)。
- 无妇科病史者手术干预风险:利伐沙班 vs 达比加群 HR 1.22(95%CI 1.05-1.42),vs 阿哌沙班 HR 1.25(95%CI 1.04-1.49),vs 华法林 HR 1.36(95%CI 1.23-1.50)。
临床怎么用
- 对育龄女性处方利伐沙班时应告知重度异常子宫出血风险。
- 尤其关注无妇科病史女性使用利伐沙班时的出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: There have been reports of clinically relevant uterine bleeding events among women of reproductive age exposed to rivaroxaban. OBJECTIVE: The aim of this study was to compare the risk of severe abnormal uterine bleeding (SAUB) resulting in transfusion or surgical intervention among women on rivaroxaban versus apixaban, dabigatran and warfarin. METHODS: We conducted a retrospective cohort study in the FDA's Sentinel System (10/2010-09/2015) among females aged 18+ years with venous thromboembolism (VTE), or atrial flutter/fibrillation (AF) who newly initiated a direct oral anticoagulant (DOAC; rivaroxaban, apixaban, dabigatran) or warfarin. We followed women from dispensing date until the earliest of transfusion or surgery following vaginal bleeding, disenrollment, exposure or study end date, or recorded death. We estimated hazard ratios (HRs) using Cox proportional hazards regression via propensity score stratification. Four pairwise comparisons were conducted for each intervention. RESULTS: Overall, there was an increased risk of surgical intervention with rivaroxaban when compared with dabigatran (HR 1.19; 95% CI 1.03-1.38), apixaban (1.23; 1.04-1.47), and warfarin (1.34; 1.22-1.47). No difference in risk for surgical intervention was observed for dabigatran-apixaban comparisons. Increased risk of transfusion was observed for rivaroxaban compared with dabigatran (1.49; 1.03-2.17) only. For patients with no gynecological history, rivaroxaban was associated with risk of surgical intervention compared with dabigatran (1.22; 1.05-1.42), apixaban (1.25; 1.04-1.49), and warfarin (1.36; 1.23-1.50). CONCLUSION: Our study found increased SAUB risk with rivaroxaban use compared with other DOACs or warfarin. Increased risk with rivaroxaban was present among women without underlying gynecological conditions. Women on anticoagulant therapy should be aware of a risk of SAUB.
引用
- Eworuke E, Hou L, Zhang R, et al. Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and Warfarin. Drug Saf. 2021. PMID: 34014506. doi:10.1007/s40264-021-01072-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。